Ozempic & Wegovy Shortage UK 2026: GLP-1 Supply Update

What Are GLP-1 Medicines?

GLP-1 receptor agonists (GLP-1 RAs) are a class of injectable medicines that mimic the action of glucagon-like peptide-1, a hormone naturally produced in the gut after eating. They work by:

• Stimulating the release of insulin in response to blood glucose
• Suppressing glucagon (which raises blood sugar)
• Slowing gastric emptying — making you feel full for longer
• Reducing appetite signals in the brain

Originally developed for type 2 diabetes, this class of medicine has transformed the treatment landscape — not just for blood sugar control, but for weight management, cardiovascular risk reduction, and (in emerging research) kidney protection and heart failure management.

The Demand Explosion: Why It Happened

The GLP-1 shortage cannot be understood without appreciating the scale and speed of the demand explosion that preceded it. Three overlapping forces drove unprecedented demand:

1. Expanded clinical evidence in diabetes

Large clinical trials — notably the SUSTAIN and LEADER programmes — demonstrated that GLP-1 receptor agonists don't just lower blood sugar. They significantly reduce cardiovascular events (heart attacks, strokes) and deaths in people with type 2 diabetes and established cardiovascular disease. This triggered updated prescribing guidelines recommending GLP-1s as a preferred second-line treatment for millions of NHS patients with type 2 diabetes who also have heart disease or high cardiovascular risk.

2. The weight loss revolution

The landmark STEP clinical trials (2021 onwards) demonstrated that high-dose semaglutide produced weight loss of 15-20% on average — far exceeding any previous anti-obesity medication. This marked a paradigm shift in obesity treatment. NHS approval of Wegovy (2023-2024) and private prescribing growth created a second, entirely separate stream of demand for semaglutide.

3. Off-label prescribing and private clinics

With Wegovy supply limited, many people sought Ozempic (the lower-dose, diabetes-licensed semaglutide) through private prescribers for weight loss. This off-label use — facilitated by a booming market of online weight loss clinics — diverted supply away from diabetes patients. At the peak of the crisis, it became difficult for some type 2 diabetes patients to obtain their prescribed Ozempic because private clinics were obtaining the same product for weight management customers.

Novo Nordisk Supply Constraints

Novo Nordisk, the Danish pharmaceutical company behind both Ozempic and Wegovy, has faced enormous pressure to scale manufacturing to meet global demand. The challenges are significant:

Biological manufacturing complexity

Semaglutide is a complex biological molecule — a long peptide chain — not a simple chemical compound. Its manufacture requires specialised bioreactors, stringent sterile conditions, and sophisticated quality controls. Building new manufacturing capacity takes years, not months. Novo Nordisk has invested billions of euros in expanding production, but these investments take time to come online.

Global demand pressure from multiple markets

The GLP-1 demand explosion is not unique to the UK — it is a global phenomenon. The United States market alone, with 130 million people with obesity or diabetes, exerts enormous demand. Novo Nordisk has had to make difficult decisions about how to allocate limited production across markets. The UK, while important, competes for supply with much larger markets.

Investment timeline

Novo Nordisk has announced multi-billion euro investments in new manufacturing facilities. Production from these investments is gradually coming online through 2025 and 2026, which is why supply has improved from the worst of the shortage — but demand continues to grow, and balance has not been fully restored.

NHS Prioritisation: Diabetes vs Weight Loss

In the UK, the NHS has made clear that people with type 2 diabetes who have been prescribed GLP-1 medicines for blood sugar control are the priority group for available supply.

NHS guidance on prescribing priority

NHS England has issued guidance to prescribers during periods of shortage, directing that:

• Ozempic (and other GLP-1s) should be prioritised for people with type 2 diabetes in whom it has been prescribed for glycaemic control
• Weight management prescribing should only begin when supply is sufficient to sustain treatment without affecting existing diabetes patients
• Off-label prescribing of Ozempic for weight loss is strongly discouraged when supply is constrained

The two-tier supply problem

A significant complication has been the existence of a substantial private prescribing market operating alongside the NHS. Private online clinics have been able to source GLP-1 medicines through the same pharmaceutical supply chain as NHS pharmacies. During shortage periods, this created competition for the same limited stock — with wealthier patients able to pay premium prices through private services while some NHS patients went without.

Regulatory responses have included calls for a formal allocation system and restrictions on private prescribing of Ozempic during shortage periods, but enforcement has been challenging.

Ozempic (Semaglutide for Diabetes)

Ozempic remains the foundation of the GLP-1 supply story. As the first semaglutide product widely prescribed, it bore the full brunt of the demand explosion. At the height of the shortage (2022-2023), NHS patients were being told to seek alternatives, and some went months without their prescribed medication.

The situation in 2026 is better. Novo Nordisk has increased production capacity, and the market has somewhat rationalised as Wegovy becomes more available for weight management patients, reducing off-label use of Ozempic. However, "improving" does not mean "solved" — pharmacists still regularly report stock-outs for specific pen sizes.

Wegovy (Semaglutide for Weight Loss)

Wegovy received MHRA approval in 2023 and NICE approval for NHS use in specific contexts from 2024. However, NICE guidance limits NHS prescribing to specialist weight management services and places conditions on eligibility (BMI thresholds, presence of weight-related comorbidities). This means most people who might benefit from Wegovy cannot currently access it through the NHS without a specialist referral.

The private Wegovy market

Wegovy is widely available through private online prescribing services in the UK. Costs typically range from £150-£300 per month for the injection pens. While this route works for those who can afford it, it places weight management access on the basis of ability to pay — and private demand competes with NHS supply.

Why can't Novo Nordisk just make more?

Novo Nordisk is making more — it has committed billions in new manufacturing capacity. However, building pharmaceutical-grade manufacturing facilities for biological medicines takes years from planning to operation. The company simply could not have predicted in 2018-2019 that demand would increase at this speed. The mismatch between the multi-year timeline of manufacturing investment and the near-instant scale-up in demand is the fundamental tension behind the shortage.

Mounjaro (Tirzepatide by Eli Lilly)

Mounjaro (tirzepatide) represents the next generation of GLP-1 therapy. It is a dual GIP/GLP-1 receptor agonist — it activates two complementary hormone receptors rather than one. Clinical trial data showed even greater weight loss than semaglutide (20-22% of body weight on average in the SURMOUNT trials), making it the most effective anti-obesity medicine currently available.

NHS access to Mounjaro

NICE approved Mounjaro for NHS use in adults with a BMI of ≥35 kg/m² (or ≥30 kg/m² for certain high-risk groups) with at least one weight-related comorbidity, through specialist weight management services. Access through general practice is not currently available, and NHS waiting lists for specialist services can be long.

Private Mounjaro

Mounjaro is widely available through UK private prescribing services. Unlike Ozempic, it has not faced the same extreme shortage pressure — Eli Lilly planned manufacturing capacity more carefully in anticipation of strong demand, and availability has been relatively stable since UK launch.

Saxenda (Liraglutide) — An Alternative That's Sometimes More Available

Saxenda (liraglutide) is the predecessor to Wegovy in the weight management space. It uses an older GLP-1 molecule (liraglutide, which is also available as Victoza for diabetes at a lower dose), requires daily rather than weekly injection, and produces less weight loss on average. Because of these limitations, demand for Saxenda dropped significantly when semaglutide became available.

The silver lining is that Saxenda's relative unpopularity means it is often easier to obtain than Ozempic or Wegovy. For patients who cannot access semaglutide or tirzepatide, Saxenda represents a clinically validated alternative — though your prescriber should counsel you on the differences in efficacy and injection frequency.

⚠️ MHRA Counterfeit Warnings: A Serious Safety Issue

The high demand and supply constraints for GLP-1 medicines have created a dangerous counterfeit market. The MHRA (Medicines and Healthcare products Regulatory Agency) has issued multiple safety alerts about fake GLP-1 products being sold online and through unregulated channels.

What the MHRA has found

• Fake Ozempic pens that look identical to genuine products but contain insulin
• Products of unknown composition sold through social media and online marketplaces
• Websites claiming to be registered UK pharmacies that are not
• Products sourced from outside the UK without appropriate regulatory oversight

How to protect yourself

• Only buy GLP-1 medicines from a pharmacy registered with the General Pharmaceutical Council (GPhC)
• Look for the EU common logo (a green cross with a flag and code) on any online pharmacy website — click it to verify registration
• Never buy Ozempic, Wegovy, or other GLP-1 medicines through social media, WhatsApp groups, or unregulated websites
• Be suspicious of prices that seem too good to be true — genuine GLP-1 medicines are expensive to manufacture
• If you receive a product that looks different from your usual supply (different pen design, different label, different feel), do not inject it and contact the MHRA or your pharmacist
• Report suspected counterfeit medicines to the MHRA via the Yellow Card scheme

What To Do If You Can't Get Your GLP-1

If you have type 2 diabetes

• Contact your GP or diabetes nurse — you are a priority patient and should receive support navigating supply issues
• Ask your pharmacist to check stock availability across their supplier network — different wholesalers may have different stock
• Ask your prescriber about alternative GLP-1 medicines (e.g., Mounjaro if Ozempic is unavailable, or Saxenda if both are scarce)
• Do not stop your GLP-1 without discussing it with your diabetes team — blood glucose can deteriorate and alternative management needs to be put in place
• Sign up for MediWatch alerts for your specific medicine

If you are on a GLP-1 for weight management

• Contact your prescribing service (NHS specialist service or private clinic) — they may have access to alternative supply routes
• Ask about Mounjaro as an alternative — it is currently more available and has excellent clinical evidence
• Saxenda (daily injection) may be available as a bridge while awaiting semaglutide supply
• Maintain lifestyle changes during any gap — stopping a GLP-1 without maintaining diet and exercise changes typically leads to weight regain
• Do not seek alternatives from unregulated sources — the counterfeit risk is real and dangerous

Frequently Asked Questions

Related GLP-1 Shortage Trackers